drugset / Trial / NCT01379807
Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Unknown
55 enrolled
Grupo Gallego de Investigaciones Oncologicas
Amgen · collabTrial Form Support S.L. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The clinical hypothesis of this study is that the addition of Panitumumab to the first line treatment combination of docetaxel plus cisplatin will provide benefit to patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Timeline
- Start
- 2010-12
- Primary completion
- 2014-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Panitumumab | Monoclonal antibody | — | — |